Mutation Mimicking Compounds for EGFR Kinase Domain Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for EGFR-related cancers are limited by their effectiveness in patients without the L858R mutation, as traditional EGFR tyrosine kinase inhibitors only benefit a small sub-population with this mutation, necessitating a broader solution to inhibit cell proliferative disorders characterized by over-activity or inappropriate activity of EGFR.
Innovation Solution
Development of small molecule compounds that mimic the L858R mutation in the EGFR tyrosine kinase domain, enhancing the binding affinity of traditional TKIs and making EGFR-expressing tumor cells more susceptible to inhibition, thereby expanding the efficacy of existing EGFR and Src tyrosine kinase inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional EGFR tyrosine kinase inhibitors are used, then tumor cells with L858R mutation show high sensitivity and response, but only a small sub-population of patients (ca. 5%) benefit from this treatment
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of TKI compounds to alter their binding characteristics. Specifically, the compounds are designed to bind to the EGFR kinase domain with high affinity and stabilize the active conformation, thereby changing the pharmacological parameters to enable effective inhibition across both mutant and wild-type EGFR, expanding patient coverage while maintaining high response rates
Solution Approach 2:
The patent achieves universality by developing TKI compounds that can effectively inhibit both mutant (L858R) and wild-type EGFR. The compounds are designed to bind to the kinase domain and stabilize the active conformation universally, making them effective across different patient sub-populations regardless of their EGFR mutation status, thus treating a broader range of cancers
2Adaptability or versatility
If mutation-mimicking compounds are introduced to expand efficacy, then treatment effectiveness increases for wider patient population, but the complexity of treatment regimen increases
Solution Approach 1:
The patent uses mutation-mimicking compounds as intermediary agents that modulate the EGFR kinase domain conformation. These compounds act as mediators between the TKI inhibitors and the EGFR receptor, stabilizing the active conformation to enhance TKI binding and efficacy. This intermediary approach allows the expansion of patient coverage without requiring complete redesign of the treatment mechanism
Solution Approach 2:
The patent employs composite therapeutic strategies by combining mutation-mimicking compounds with traditional TKI inhibitors. This composite approach integrates the conformational stabilization function of the mutation-mimicking compounds with the inhibitory function of the TKIs, creating a synergistic treatment regimen that expands efficacy while managing complexity through coordinated action of two compound classes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds increase the sensitivity of EGFR-expressing tumor cells to traditional TKIs, leading to enhanced inhibition of cell proliferation and apoptosis, improving treatment outcomes for a wider range of patients with EGFR-related cancers by stabilizing the active form of the EGFR kinase and increasing the affinity of TKIs for the EGFR kinase domain.
Implementation Method 1
These compounds bind to the kinase domain of EGFR and stabilize the active form of the kinase, increasing the affinity of TKIs for the EGFR kinase domain
Data Source
AI summary
This invention is in the fields of cancer therapy. More particularly it concerns compounds which are useful agents for treating cell proliferative disorders, especially those disorders characterized by over activity and/or inappropriate activity of a EGFR, including EGFR-related cancers, particularly for expanding the efficacy of drugs previously developed for this purpose, and for methods of treatments using the compounds for this purpose.